300. IgG4-related disease Clinical trials / Disease details

Clinical trials : 36 / Drugs : 49 - (DrugBank : 22) / Drug target genes : 16 - Drug target pathways : 98

diseases per page:

Showing 1 to 10 of 36 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04602598 (ClinicalTrials.gov)	January 15, 2022	20/10/2020	Zanubrutinib in Patients With IgG4-Related Disease	A Phase II, Single-Site, Open-Label Study of Zanubrutinib in Patients With IgG4-Related Disease	IgG4 Related Disease	Drug: Zanubrutinib 80 MG	Matthew C. Baker	Stanford University	Not yet recruiting	18 Years	85 Years	All	10	Phase 2	United States
2	NCT04918147 (ClinicalTrials.gov)	October 13, 2021	4/6/2021	Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)	Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)	IgG4 Related Disease;IgG4-RD	Drug: elotuzumab;Drug: placebo for elotuzumab;Drug: methylprednisolone;Drug: diphenhydramine;Drug: a ...	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence;Bristol-Myers Squibb;Rho Federal Systems Division, Inc.	Active, not recruiting	18 Years	70 Years	All	75	Phase 2	United States
3	JPRN-jRCT2071210001	18/08/2021	01/04/2021	A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease	A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy ...	IgG4-Related Disease	RCP: Blinded treatment on Day 1, Day 15, and Week 26: - Inebilizumabgroup: Inebilizumab300 mg intrave ...	Katayama Sota	NULL	Recruiting	>= 20age old	Not applicable	Both	16	Phase 3	USA;China;Australia;Canada;France;Italy;Germay;Hong Kong;Hungary;Israel;Ireland;Mexico;Netherlands;P ...
4	EUCTR2020-000417-33-SE (EUCTR)	30/03/2021	19/11/2020	Inebilizumab efficacy and safety in IgG4 related disease	A Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy ...	Immunoglobulin G4-related disease (IgG4-RD) MedDRA version: 20.0;Level: PT;Classification code 10077 ...	Trade Name: Uplizna Product Name: Inebilizumab INN or Proposed INN: INEBILIZUMAB Other descriptive name ...	Viela Bio, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	200	Phase 3	Sweden;Japan;China;Germany;Netherlands;Australia;Poland;Argentina;Canada;Mexico;Hungary;France;India ...
5	EUCTR2020-000417-33-NL (EUCTR)	26/02/2021	29/09/2020	Inebilizumab efficacy and safety in IgG4 related disease	A Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy ...	Immunoglobulin G4-related disease (IgG4-RD) MedDRA version: 20.0;Level: PT;Classification code 10077 ...	Trade Name: Uplizna Product Name: Inebilizumab INN or Proposed INN: INEBILIZUMAB Other descriptive name ...	Viela Bio, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	200	Phase 3	United States;Hong Kong;Spain;Ukraine;Ireland;Turkey;Israel;United Kingdom;Italy;India;France;Hungar ...
6	NCT04660565 (ClinicalTrials.gov)	January 2021	23/9/2020	Belimumab Treatment for IgG4-related Disease	Belimumab Treatment for IgG4-related Disease, a Prospective, Open-label Clinical Trial	IgG4-related Disease	Drug: Prednisone and Belimumab;Drug: Prednisone	Peking Union Medical College Hospital	NULL	Recruiting	18 Years	75 Years	All	60	Phase 4	China
7	EUCTR2020-000417-33-IT (EUCTR)	16/12/2020	21/10/2020	Inebilizumab efficacy and safety in IgG4 related disease	A Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy ...	Immunoglobulin G4-related disease (IgG4-RD) MedDRA version: 20.0;Level: PT;Classification code 10077 ...	Product Name: Inebilizumab Product Code: [Inebilizumab] INN or Proposed INN: Inebilizumab Other descrip ...	VIELABIO Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	200	Phase 3	United States;Spain;Ukraine;Israel;United Kingdom;Italy;India;France;Hungary;Mexico;Canada;Poland;Au ...
8	NCT04540497 (ClinicalTrials.gov)	October 26, 2020	1/9/2020	A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease	A Phase 3, Randomized, Double-blind, Multicenter, Placebo Controlled Study of Inebilizumab Efficacy ...	IgG4 Related Disease	Drug: Inebilizumab;Other: Placebo	Viela Bio	NULL	Recruiting	18 Years	N/A	All	160	Phase 3	United States;Argentina;Australia;Canada;China;France;Germany;Hong Kong;Hungary;India;Ireland;Israel ...
9	EUCTR2020-000417-33-HU (EUCTR)	06/10/2020	06/08/2020	Inebilizumab efficacy and safety in IgG4 related disease	A Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy ...	Immunoglobulin G4-related disease (IgG4-RD) MedDRA version: 20.0;Level: PT;Classification code 10077 ...	Product Name: Inebilizumab INN or Proposed INN: INEBILIZUMAB Other descriptive name: afucosylated IgG1 ...	Viela Bio, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	200	Phase 3	United States;Spain;Ukraine;Israel;United Kingdom;Italy;India;France;Hungary;Mexico;Canada;Poland;Au ...
10	EUCTR2020-000417-33-DE (EUCTR)	30/09/2020	24/06/2020	A Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy ...	A Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy ...	Immunoglobulin G4-related disease (IgG4-RD) MedDRA version: 20.0;Level: PT;Classification code 10077 ...	Trade Name: Uplizna Product Name: Inebilizumab INN or Proposed INN: INEBILIZUMAB Other descriptive name ...	Viela Bio, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	200	Phase 3	United States;Hong Kong;Spain;Ukraine;Ireland;Turkey;Israel;United Kingdom;Italy;India;France;Hungar ...

First Previous1 2 3 4Next Last